Alphagan P Essays -- Drugs, Treating Glaucoma

at that place has been a new step in science leading towards evolution. Alphagan P has been recognized as the next leading pharmaceutical in treating Glaucoma. It is pleasing to the ocular surface, unlike other medications which can harm it. Alphagan P provides IOP weighed down which is comparable to beta blocker, but is without the unseemly affects that virtually other medications ca spend. It is an alpha-2 agonist, which is a class of drugs that bind to and stimulate alpha-2 adrenergic receptors, causing responses comparable to those of adrenaline and noradrenaline.Alphagan was first introduced in 1996. The latest generation of adrenergic agonist is thrity measure more selective for alpha 2 receptors than apraclonidine. Beca enforce of its selectivity, it does not include the alpha 1 grimace effects that affect the heart and blood pressure. The most significant side effects are drowsiness, a dry mouth, and fatigue. in that respect is also surface irritation, with more or l ess 7 to 15 percent of patients experiencing allergic conjunctivitis. Alphagan has stayed popular since it first came out despite its side effects. What should you know about Alphagan P before using it? Make sure to not use brimonidine ophthalmic (Alphagan P) if you have used an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 2 weeks. Inform your rectify if you have kidney or liver disease, heart disease, circulation problems such as Raynauds or Buergers disease, high blood pressure, have a history of fainting or low-pitched blood pressure. Make sure to not use the medication if you use contact lenses because the medication contains a preservative that can be absent-minded by soft contact lenses. If ... ...wing through with their education. Studies are now being done to further investigate this occurrence. Although Alphagan P has a list of adverse reactions rep orted, it is still the most used medication used to treat patients with Glaucoma. some(prenominal) clinical studies have been done on the drug since it came out in 1996, and further enhancements have been made since.Works CitedOsborne, S., Montgomery, D., Morris, D., & McKay, I. (2005). Alphagan allergy may profit the propensity for multiple eye-drop allergy. Eye, 19(2), 129-137. doi10.1038/sj.eye.6701441Bowman, R. C., Cope, J. J., & Nischal, K. K. (2004). Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Eye, 18(1), 24-26. doi10.1038/sj.eye.6700520ALPHAGAN P THE NEXT bar IN THE EVOLUTION OF GLAUCOMA THERAPY. (2003). Review of Ophthalmology, 10(9), 8.